AbbVie CEO reports tax-withholding share disposition

AbbVie Inc. director and CEO Michael Robert A. reported a Form 4 transaction involving a tax-related share disposition.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

AbbVie Inc. director and CEO Michael Robert A. reported a Form 4 transaction involving a tax-related share disposition. On February 27, 2026, he had 36,523 shares of common stock disposed of at $232.08 per share to satisfy tax obligations. After this tax-withholding disposition, he directly owned 178,737 shares of AbbVie common stock.

Insider Trade Summary

Exercise Price or Tax Liability: 36,523 shares

Exercise Price or Tax Liability 1 txn

Insider Michael Robert A.

Role CHAIRMAN OF THE BOARD AND CEO

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock, $0.01 par value	36,523	$232.08	$8.48M

Holdings After Transaction: Common Stock, $0.01 par value — 178,737 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AbbVie (ABBV) report for Michael Robert A.?

AbbVie reported that Michael Robert A., its chairman and CEO, had 36,523 common shares disposed of on February 27, 2026, as a tax-withholding transaction. The shares were valued at $232.08 each, according to the Form 4 filing data.

Was the AbbVie (ABBV) insider transaction an open-market sale?

No, the AbbVie insider transaction was classified as a tax-withholding disposition, not an open-market sale. The Form 4 uses code F, indicating shares were delivered to cover tax liabilities associated with equity compensation rather than sold on the open market.

How many AbbVie (ABBV) shares did Michael Robert A. dispose of for taxes?

Michael Robert A. disposed of 36,523 AbbVie common shares in a tax-withholding transaction. The Form 4 shows these shares were valued at $232.08 per share and were used to satisfy tax obligations tied to an equity award event.

How many AbbVie (ABBV) shares does Michael Robert A. hold after the Form 4 transaction?

After the tax-withholding disposition, Michael Robert A. directly held 178,737 AbbVie common shares. This post-transaction balance is reported in the Form 4 as “shares owned following transaction,” reflecting his remaining direct ownership stake in the company.

What does transaction code F mean in the AbbVie (ABBV) Form 4 filing?

Transaction code F in the AbbVie Form 4 indicates a tax-withholding disposition. This means shares were delivered to satisfy the exercise price or tax liability arising from an equity award, rather than being voluntarily bought or sold on the open market.

Is the AbbVie (ABBV) Form 4 transaction classified as a buy or sell?

The AbbVie Form 4 transaction is classified as a disposition for tax withholding, not a traditional buy or sell. The filing describes it as payment of tax liability by delivering securities, with no open-market purchase or sale reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/03/2026 - 06:12 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Michael Robert A.

(Last)

(First)

(Middle)

1 N. WAUKEGAN ROAD

(Street)

NORTH CHICAGO

60064

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
AbbVie Inc. [ ABBV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHAIRMAN OF THE BOARD AND CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, $0.01 par value	02/27/2026		F		36,523	D	$232.08	178,737	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

	/s/ T.O. Odutayo, Attorney-in-Fact for Robert A. Michael	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR